Please see below for a list of search results.
This document describes the HTA’s policy on the management and traceability of tissue samples retained by independent pathologists when undertaking post mortem examinations (PME) at HTA-licensed premises where they are not employed.
The aims of this policy are:
Download these standards as a printable PDF.
This position statement outlines guidance provided on consent for post-mortem examination and tissue retention.
The Human Tissue Act 2004 requires that the removal of tissue from the deceased for research within the scope of the Act must always be licensed, on specified premises, and that specific minimum requirements are met.
Consent underpins the Human Tissue Act (2004) (HT Act). This section explains the consent exemptions from the Act.
This policy describes the Human Tissue Authority’s (HTA’s) policy on the sale of human bodies, body parts and tissue.Purpose
The purpose of this policy is to inform stakeholders of the HTA’s position on the sale of human bodies, body parts or tissue.
Issued 15 April 2009
A person with haemophilia has been found to have evidence of infection with the agent (abnormal prion protein) that causes variant Creutzfeldt-Jakob Disease (vCJD), only in his spleen, at post mortem.